On March 1, 2023, genomic medicine company Chroma Medicine announced that it had completed a $135 million Series B financing, which was led by GV (Google Ventures). The financing included additional participation from new investors ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, and all of its existing investors, including Alexandria Venture Investments, Atlas Venture, Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners, Omega Funds, Osage University Partners, Sofinnova Partners, T Rowe Price, and Wellington Management. Wilson Sonsini Goodrich & Rosati represented Chroma Medicine on the transaction.

Chroma Medicine has pioneered single-dose epigenetic editing therapeutics. The company plans to use the proceeds to support the advancement of its therapeutic programs, as well as a continued investment in its core epigenetic editing platform.

Wilson Sonsini previously advised Chroma Medicine on a $125 million financing when the company launched in December 2021. The team advising on this financing includes Lou Lieto, Angel Wang, Sarah Cohen, and Payal Vyas. For additional information, please see the company’s press release.